Two powerhouses join forces to examine how oxidation affects antibody therapeutics

Antibodies are one of the most common types of drugs in the biopharmaceutical industry and play a key role in the treatment of several diseases. This is in part due to the ability to modify and enhance their specificity to their interaction target. However, the biggest challenge for their development is maintaining the chemical and structural integrity during manufacturing, formulation, and storage.

A major concern is oxidation, one of the most widely observed causes of antibody degradation. It can result in loss of biological activity or efficacy, shortened half-life and even adverse immunogenic reactions when administered in patients. Therefore, having robust technologies to screen and evaluate its effects on both stability and functionality of these biotherapeutics is crucial to minimize downstream risks.


The power of two: evaluating structural integrity and functionality to guarantee quality

In this application note, learn how Tycho was used to quickly evaluate the impact of oxidation on the structural integrity of the therapeutic monoclonal antibody Trastuzumab. Moreover, learn how Tycho was combined with Monolith which runs MicroScale Thermophoresis (MST) in a follow-up screen to further assess the effects on the antibody’s binding capability, allowing to establish a correlation between oxidation-driven effects on stability and binding affinity.

The use of these two complementary platforms is a fast and low sample consuming approach that facilitates the monitoring of antibody quality during the development phase, contributing to accelerate the development of better therapeutics.

Download this application note to learn more.